A high dose of sickle cell drug pociredir boosted fetal hemoglobin and reduced red blood cell destruction in adults with ...

As they shift from pediatric to adult care, young adult patients with sickle cell disease appear to visit the ER more often, a study found.

A clinical trial testing the oral therapy tebapivat for sickle cell disease is fully enrolled, with early results expected later this year.

Wilson explains how new experiences help him gather evidence that things can go well, even with sickle cell disease.

Differences in red blood cell stiffness may help to explain variations in the severity of sickle cell disease (SCD), ...

Chronic pain among adolescents and young adults with sickle cell disease (SCD) is associated with more functional disability — meaning patients are less able to independently perform daily activities ...

Higher levels of fetal hemoglobin (HbF) seem to protect people with sickle cell disease (SCD) by reducing the risk of lung problems, such as pulmonary hypertension, and delaying bone damage, at least ...

Emmaus Life Sciences has entered into an agreement to sell the North American rights to Endari (oral L-glutamine), its oral treatment to prevent acute complications related to sickle cell disease (SCD ...

As part of my advocacy, I frequently deliver keynote speeches and participate in panel discussions, and I’m often asked a particular question: “Is sickle cell disease a disability?” My answer is ...

Big Nova has made a $3 million donation to support NMDP’s efforts to help more patients, including those with sickle cell disease (SCD), access blood stem cell transplants. The philanthropic gift ...

Risto-cel, Beam Therapeutics‘ single-dose, gene-edited cell therapy candidate for people with severe sickle cell disease (SCD), continues to demonstrate sustained therapeutic benefits for as long as ...

The European Medicines Agency (EMA) has confirmed the continuing suspension of marketing authorization for Pfizer’s sickle cell disease (SCD) treatment Oxbryta (voxelotor) — withdrawn from the market ...